Life Science

Tue, 12/09/2017 - 08:00
Poster and Oral Presentation at the 19th RSC / SCI Medicinal Chemistry Symposium, 10th-13th September 2017, Churchill College, Cambridge, UK
The Roslin Innovation Centre
Mon, 11/09/2017 - 07:30
Edinburgh, UK, 11th September 2017 / Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the
Fri, 08/09/2017 - 07:30
London, UK, 8th September 2017 / Sciad Newswire / On 14th September, 250 leading lights, emerging stars, C-suite executives, impactful investors and po
Tue, 05/09/2017 - 07:30
Challenge trial will evaluate RV521 in approximately 70 volunteers
Wed, 30/08/2017 - 15:30
London, UK, 25th August 2017 / Sciad Newswire / Touchlight Genetics Ltd has developed a revolutionary DNA technology that can synthetically manufacture commercial
Fri, 21/07/2017 - 07:30
London, UK, 21st July 2017 / Sciad Newswire / A survey of synthetic biology company start-ups in the UK is published today by  
Thu, 20/07/2017 - 10:59
Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US trial of its MiCheck® prostate cancer screening test.​
Wed, 12/07/2017 - 12:23
London, UK, 12th July 2017 / Sciad Newswire / SynbiCITE and Rainbow Seed Fund co
Thu, 29/06/2017 - 07:30
Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.